Great share structure. Just a matter of time before this gem is discovered

This news is on my TDA account; didn’t see it anywhere else:

7:15a ET 12/14/2021 - Globe Newswire
Early Warning Report filed pursuant to National Instrument 62-103
Mentioned: BABYF
Pursuant to National Instrument 62-103, The Early Warning System and Related Take-Over Bids and Insider Reporting Issues, Ms. Hamutal Yitzhak and Mr. Uriel Kesler (together, the "Filers") were each required to file an early warning report in relation to their respective change in holdings of the 104,196,220 outstanding common shares (each, a "Share") in the capital of Else Nutrition Holdings Inc. (the "Issuer") by more than 2% from the date of their previously filed early warning reports.

Ms. Hamutal Yitzhak's Early Warning Report

Effective December 12, 2021, Ms. Yitzhak ceased to exercise voting control or direction (the "Deemed Disposition") over an aggregate of 599,995 Shares, pursuant to the voting support agreements more particularly described in Ms. Yitzhak's early warning report dated December 14, 2020. Since the date of the prior report, Ms. Yitzhak's holdings in the Share class decreased from approximately 16.20% (as of December 14, 2020) to approximately 13.74% of the current outstanding Shares. This represents an overall decrease of approximately 2.46%, on a partially-diluted basis, assuming the exercise of 488,184 stock options to acquire Shares (each, an "Option") which are beneficially held by Ms. Yitzhak and are exercisable today or within 60 days.

Immediately prior to the Deemed Disposition, Ms. Yitzhak held beneficial ownership, direction or control over an aggregate of 14,430,012 Shares and 481,944 Options, representing approximately 13.84%, on a non-diluted basis, and approximately 14.31%, on a partially-diluted basis, of the current outstanding Shares, assuming the deemed exercise of the 481,944 Options.

Immediately after the Deemed Disposition, Ms. Yitzhak held or is deemed to hold beneficial ownership, direction or control over, an aggregate of 13,830,017 Shares and 488,194 Options, representing approximately 13.27%, on a non-diluted basis, and approximately 13.74%, on a partially-diluted basis, of the current outstanding Shares, assuming the deemed exercise of 488,194 Options. The holdings include the vested portion of the 75,000 Options granted to Ms. Yitzhak on November 12, 2021, as more particularly described in the Issuer's press release dated November 12, 2021, and the balance of the 599,995 Shares over which Ms. Yitzhak continues to exercise voting control or direction in accordance with the voting support agreements.

Mr. Uriel Kesler's Early Warning Report

Effective December 12, 2021, Mr. Kesler was deemed to have acquired voting control and direction over an additional 6,250 Shares as a result of the vesting of a portion of the 75,000 Options granted to Mr. Kesler on November 12, 2021 (the "Vested Options"). Since the date of Mr. Kesler's prior early warning report dated June 13, 2019, Mr. Kesler's holdings in the Share class decreased from approximately 19.71% (as of June 13, 2019) to approximately 13.15% of the current outstanding Shares. This represents an overall decrease of approximately 6.54%, on a partially-diluted basis, assuming the exercise of 474,306 Options which are beneficially held by Mr. Kesler and are exercisable today or within 60 days.

Immediately prior to the Vested Options, Mr. Kesler held beneficial ownership, direction or control over an aggregate of 13,230,012 Shares and 481,944 Options, representing approximately 12.70%, on a non-diluted basis, and approximately 13.15%, on a partially-diluted basis, of the current outstanding Shares, assuming the deemed exercise of the 481,944 Options.

Immediately after the Vested Options, Mr. Kesler held or is deemed to hold beneficial ownership, direction or control over, an aggregate of 13,230,012 Shares and 488,194 Options, representing approximately 12.70%, on a non-diluted basis, and approximately 13.16%, on a partially-diluted basis, of the current outstanding Shares, assuming the deemed exercise of 488,194 Options.

Immediately after the Vested Options, Mr. Kesler held or is deemed to hold beneficial ownership, direction or control over, an aggregate of 13,230,012 Shares and 474,306 Options, representing approximately 12.70%, on a non-diluted basis, and approximately 13.15%, on a partially-diluted basis, of the current outstanding Shares, assuming the deemed exercise of 474,306 Options.

The Shares and Options (together, the "Securities") are held by the Filers for investment purposes. While each respective Filer currently has no plans or intentions with respect to the Issuer's Securities, depending on market conditions, general economic and industry conditions, trading prices of the Issuer's Shares, the Issuer's business, financial condition and prospects and/or other relevant factors, the Filers may develop such plans or intentions in the future and, at such time, may from time to time acquire additional Securities, dispose of some or all of the existing or additional Securities or may continue to hold the Securities of the Issuer.

A copy of the early warning report in respect of the foregoing matters will be available on the Issuer's profile on SEDAR at www.sedar.com.

The head office of the Issuer is located at 6 Hanechoshet St., Tel Aviv, Israel, 6971070.

So first, let me thank @shibainuart for being the catalyst for this momentous occasion! For months #ShibArmy has requested a BURN and today we are happy to announce a partnershib that does this and much more. I'll brief here... 1/5

— Shytoshi Kusama™ (@ShytoshiKusama) October 7, 2021

https://www.otcmarkets.com/filing/html?id=15247367&guid=0P-wkHvy7FiCW3h

https://twitter.com/normallmr/status/1439625295363985415?s=21

$ATER short interest is $36M
5.59M shares shorted
24.27 % SI% of Float
19.53 % S3 SI% Float
20.07 % fee
Shares shorted up +85K shs, worth $552K, 1.55 %, over the last week.
Shorts up +$69M in 2021 mark-to-market profits;
including +$277K on today's -0.78 % move. pic.twitter.com/ofQkX6VdHS

— Ihor Dusaniwsky🇺🇦 (@ihors3) September 3, 2021

HUT8 on CNBC

https://www.cnbc.com/video/2021/09/03/big-call-buying-in-this-mining-stock.html

TD delaying until the end of the month?? You POS mofo. @TDAmeritrade Guess I don’t have to worry about this Friday. Time to buy!!

— Chase🦈 (@ChaseMacTrades) August 11, 2021

KROGER

https://finance.yahoo.com/news/else-nutrition-launch-kroger-owned-110000173.html


Else Nutrition Holdings Inc.
Mon, August 9, 2021, 7:00 AM
Else readying for distribution at online platforms of Nation’s Leading Grocery Retail Chain

VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) ("Else" or the "Company") the plant-based baby, toddler and children nutrition company, announces that it will be expanding into owned online marketplaces by Q4, 2021 with its Plant-Based Complete Nutrition products for Toddlers. The expansion also will place else at Kroger-owned Vitacost.com, an E-commerce leader in the healthy/organic foods space.

“Being a part of Kroger’s E-commerce platforms mark a major step forward for our online growth strategy,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “Kroger’s large on-line presence as a grocery leader, will significantly increase the accessibility of our clean label, whole food-based early nutrition products for thousands of families nationwide,” she added.


Else Nutrition is currently onboarding with Kroger Ship (of the Kroger Company), with plans to ship to Kroger customers through the Kroger.com and Vitacost.com grocery websites. Kroger Ship enables U.S. consumers the benefits of big box shopping from the comfort of your own home. Consumers can buy in bulk, browse a wide selection of products, and get access to exclusive savings.

Kroger, the nation’s largest grocery chain, saw its e-commerce sales jump by 79% in 2020, according to eMarketer, with $11.18 billion in digital sales. Riding the success of its ongoing investments in e-commerce and powered by a COVID-19 surge in online grocery sales, The Kroger Co. entered eMarketer’s annual list of Top 10 U.S. Retail E-Commerce Companies.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

Media Contact
Erin Jundef
Brilliant PR
erinj@brilliantpr.com

For more information, contact:
Mrs. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: hamutaly@elsenutrition.com
P: +972(0)3-6445095

Mr. Sokhie Puar, Director of Else Nutrition
E: sokhiep@elsenutrition.com
P: 604-603-7787

US Investor Relations Contact
Lytham Partners, LLC
Mr. Ben Shamsian
New York | Phoenix
E: shamsian@lythampartners.com
P : 646-829-9701

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

https://finance.yahoo.com/news/else-launches-clinical-study-children-110000492.html

Else Launches Clinical Study with Children’s Hospital Colorado and Denver School of Medicine to Validate Growth Benefits of Else’s Plant-Based Nutrition

Else Nutrition Holdings Inc.
Thu, July 29, 2021, 7:00 AM·3 min read
Study to compare 4-month period consumption of Else Plant-Based Toddler Nutrition vs. Consumption of Cow Milk-Based Formula

VANCOUVER, British Columbia, July 29, 2021 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) ("Else" or the "Company") the plant-based baby, toddler and children nutrition company, announces the launch of a clinical study aimed at validating its toddler and kids products support growth benefits in healthy young children vs. cow-milk-based formula. The study will be led be Prof. David Fleischer, and Prof. Carina Venter from the Allergy and Immunology Center, Children's Hospital Colorado and University of Colorado Denver School of Medicine. Prof. David Fleischer, and Prof. Carina Venter are leading research in the field of food allergy prevention and working with children with food allergies.

This study is part of the overall efforts to establish the scientific basis for the safety and tolerance of Else Nutrition products. It will follow healthy toddlers for four months, comparing growth and wellness versus those consuming a commercial cow milk -based toddler product.

- ADVERTISEMENT -

“This is an exciting development for the brand, and we are confident that it will further validate the efficacy of our whole food-based nutrition products for early childhood,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “Thousands of families across North America have already taken to Else products, and we’ve been hearing tremendous feedback, including real life-improving cases. This study will only serve as further validation, and can serve us in our Medical Marketing efforts,” she added.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

https://in.style.yahoo.com/else-nutrition-may-lead-next-131526258.html

New Seeking Alpha Article

Else Nutrition's Fast Growth Formula
Jun. 27, 2021 10:31 AM ETElse Nutrition Holdings Inc. (BABYF)7 Comments5 Likes
Sergio Heiber profile picture.
Sergio Heiber
2.84K Followers
Bio
Follow
Long-Term Horizon, Disruptor

Contributor Since 2011

I write mostly about micro-cap companies that are in the early stages of commercialization or a strategy shift. I take small initial positions in the companies that I write about. I add shares if the fundamentals remain intact and provide follow up articles on these stocks describing progress and a review of the company strategy. I stick with these companies as long as the fundamentals hold up. My investment style is not suitable for everyone as it involves high risk/high reward. The majority of start-ups fail.

You can find my stock-picking record at https://www.tipranks.com/bloggers/sergio-heiber

I am also a partner and contributor at Infovisualinvesting.com and a member of Micro Cap Club.





Summary

Else reached almost $1 million in revenue in its first quarter with combined online and retail sales.
Despite the early success of the commercial rollout, the stock price has been in a decline.
The company is expanding products offered and entering new territories, which should accelerate its growth rate.
Else is in a position to grow revenues at an over 100% rate for the next few years, reaching $1 billion in revenue within 5 years.
Buckwheat flowers
scisettialfio/iStock via Getty Images
This is a follow-up article to Else Nutrition Is As Good As Mother's Milk As You Can Get. Else Nutrition Holdings (OTCQX:BABYF) [TSX: BABY] is a plant-based, non-dairy, non-soy food and nutrition company that began commercial sales in the U.S. in the second half of 2020. Initial sales began online through the company's website in August and Amazon in September. Retail sales commenced in the fourth quarter last year. The company is executing its plan perfectly, captivating shelf space across the country and reporting revenue over 100% higher on a y/y basis. Still, the stock price has been in decline, presenting a compelling investment opportunity.


Chart
Data by YCharts
Fast growth

Else went from zero retail presence to being listed in over 900 retail outlets in just one quarter. After completing just one-quarter of combined online and retail sales, revenues reached just short of U.S. $1 million for the first quarter of 2021. Last week, a corporate update reported that sales through Amazon were growing at an annualized rate of 240%.

The growth rate will not slow down as Else will continue expanding its footprint in the U.S., introducing new products, and entering new territories. New retail outlets have been announced almost weekly. The company introduced its second commercial product just a few weeks ago; plant-based complete nutrition for kids 3-8 years old, and plans to introduce several new products in the next few months. Please refer to my earlier article or the company's investor website for details about new products expected. Expansion into Canada's brick and mortar retail outlets is slated for this year. Expansion into Europe is expected later this year or early next year, and sales will commence in China in the second half of 2022.

Financial

There are 95 million shares. There is skin in the game as insiders own over a third of the shares. Hong Kong-based Health and Happiness International have taken an 11% interest in Else. The market cap at the stock price of $2.12/share is $201 million. There is no debt, and the company has about $15 million in cash. The company has sufficient funds to manage operations. Still, another capital raise will be necessary as management plans to acquire its own production and packaging facility to improve profit margins. To preserve or accelerate the current growth rate, Else will need to expand capacity. I would expect Else to simultaneously apply for a Nasdaq listing when they do their next capital raise.

The EV is $186 million. Analyst estimates for 2021 revenue are $2.3 million. I don't expect revenue to drop on a sequential basis, so I set my target at a minimum of $4 million for 2021 revenue and $10 million for 2022, resulting in a forward P/S of 18x. It's a bit pricey but justified when considering the growth rate exceeds 100%.


The big kicker for revenue growth will be FDA and European regulatory approval for infant milk, which is a couple of years away. Gaining regulatory certification will give Else the market opportunity of being the only plant-based, non-dairy, non-soy infant food equal in nutrition to mother's milk. I see Else reaching $1 billion in sales within 5 years.

Where improvements are needed

I have a one-year-old granddaughter. I asked her mom if she had heard of Else and had tried it. She said she had not heard of Else and would ask her pediatrician. It turned out the pediatrician had never heard of Else. I spoke to pediatricians myself, and they were also unfamiliar with Else. Still, when they reviewed the information on the Else website, they found the product appealing and hope that Else reaches out to them with more information. Where I see the problem is that many parents will ask for their doctor's advice on their child's nutrition. Without reaching out to these doctors, Else is missing opportunities.

In all fairness to Else, it needed to get the product distributed and available to purchase as a priority, and they've done a marvelous job in this regard. Clinical studies supporting Else's nutritional benefits are critical in winning over pediatricians. Else has probably been waiting for the results of these studies to become public before reaching out to doctors. The clinical trial results are expected soon, and Else has included creating an information campaign for health care professionals in their recent company outlook.

I suggested to Else management that they also reach out to schools. We have an obesity problem in our country. Else offers an alternative to cow's milk, but it can be a substitute for juice. Else has a much lower sugar content than milk, juice, or competing products.

Many plant-based, non-soy, non-dairy shakes have hit the marketplace, such as Orgain and PediaGain. Else contains less sugar than these other products, but Else also contains only whole food ingredients while competitors use chemical derivatives, according to Else management. Else needs to differentiate its products from the competition better.

Risks

The company does not have much commercial history, and management lacks experience in global scaling.

Capital raises are likely to be necessary over the next two years, diluting earnings.

The company is dependent on third parties for production, packaging, and distribution.

This start-up company presents a greater risk than an established company, as most start-ups fail.


Conclusion

Else has been very successful in establishing an online and a national retail presence. The company has a short history, but it is growing revenues at an over 100% rate. Continued development of its business plan includes introducing new products and expanding into new territories, which will accelerate the growth rate. Despite the early success of the commercial roll-out, the stock price has been in decline and presents an investment opportunity for those that see the potential for Else's continued growth.

This article was written by

Sergio Heiber profile picture.
Sergio Heiber
2.84K Followers
Follow
I write mostly about micro-cap companies that are in the early stages of commercialization or a strategy sh... more
Long-Term Horizon, Disruptor

Contributor Since 2011

I write mostly about micro-cap companies that are in the early stages of commercialization or a strategy shift. I take small initial positions in the companies that I write about. I add shares if the fundamentals remain intact and provide follow up articles on these stocks describing progress and a review of the company strategy. I stick with these companies as long as the fundamentals hold up. My investment style is not suitable for everyone as it involves high risk/high reward. The majority of start-ups fail.

You can find my stock-picking record at https://www.tipranks.com/bloggers/sergio-heiber

I am also a partner and contributor at Infovisualinvesting.com and a member of Micro Cap Club.





Disclosure: I am/we are long BABAYF. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Correct link below, click image:

https://stocktwits.com/N1NJAy/message/348009087

Very nice

https://finance.yahoo.com/news/pacific-biosciences-rady-children-institute-200500343.html

HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencing

MENLO PARK, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Rady Children’s Institute for Genomic Medicine (RCIGM), a mission-driven, non-profit seeking to save lives and improve outcomes for patients, clinicians and families, shared today that they are collaborating on a study which aims to identify potential disease-causing genetic variants and increase the solve rates of rare diseases.

The study is focused on long-read whole genome sequencing of rare disease cases for which previous short-read whole genome and exome sequencing yielded no answers. The study, which is currently underway, was able to detect variants that were not identified by short-read sequencing (SRS); of these, an average of 37 were missense mutations in known disease genes.


“PacBio HiFi sequencing can identify numerous variants, both small and structural that are not readily detectable by SRS,” said Matthew Bainbridge, Principal Investigator, and Associate Director of Clinical Genomics at RCIGM. “We sequenced this cohort of patients to 10-30X depth of coverage using Pacific Biosciences HiFi long-read technology to assess whether there was an increase in the identification of these variants. We are very pleased by the preliminary results delivered in this collaboration with the team at PacBio.”

It is estimated that as many as 25 million Americans — approximately 1 in 13 people — are affected by a rare, and often undiagnosed condition. In rare disease studies, conventional techniques for whole-genome and whole-exome analysis based on SRS typically led to identification of a causal variant in less than 50% of cases. Utilizing PacBio’s Single Molecule, Real-Time (SMRT®) Sequencing technology to generate highly accurate long-reads, known as HiFi reads, clinical researchers have demonstrated that they can detect disease-causing structural and small variants missed by short-read sequencing platforms. This study is designed to evaluate the rate at which HiFi sequencing identifies overlooked causal variation.

“It is an honor to collaborate with the innovative pediatric translational researchers at RCIGM to bring HiFi Sequencing data to bear on some of their most difficult cases of rare pediatric disease, and hopefully give individuals and families answers regarding potential underlying genetic variants, which may ultimately provide healthcare providers with insights to end their diagnostic odysseys,” said Christian Henry, CEO and President at PacBio.

“We’ve been aware that there’s a subset of seriously ill babies and children who don’t receive a diagnosis with current sequencing methods, but based on their symptoms, we’re fairly certain that they have an underpinning genetic disease,” said Stephen Kingsmore, MD, DSc, President and CEO of Rady’s Children’s Institute for Genomic Medicine. “With this new technology, we are excited to see how many more of these children and families will receive additional insight regarding the identification of potential disease-causing genetic variants.”

About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.

About Rady Children’s Institute for Genomic Medicine
We are transforming pediatric critical care by advancing disease-specific healthcare for infants and children with rare disease. Discoveries at the Institute are enabling rapid diagnosis and targeted treatment of critically ill newborns and pediatric patients at Rady Children’s Hospital-San Diego and a growing network of more than 60 children’s hospitals nationwide. The vision is to expand delivery of this life-changing technology to enable the practice of Rapid Precision Medicine™ at children’s hospitals across the nation and the world. RCIGM is a non-profit, research institute of Rady Children’s Hospital and Health Center. Learn more at www.RadyGenomics.org. Follow us on Twitter and LinkedIn.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to the collaboration between PacBio and RCIGM, potential use of SMRT sequencing technology to identify, and increase the rate of identification of, potential disease-causing genetic variants in rare disease, the potential of HiFi data, the applications, insights, and attributes of SMRT sequencing technology, and the benefits of PacBio sequencing. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements contained in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Forms 8-K, 10-K, and 10-Q. The Company disclaims any obligation to update or revise any forward-looking statements.

Contacts

Investors:
Todd Friedman
+1 (650) 521-8450
ir@pacificbiosciences.com

Media:
Jen Carroll
+1 (858) 449-8082
pr@pacificbiosciences.com

https://finance.yahoo.com/news/corporate-growth-online-sales-retail-110000642.html

Wed, June 23, 2021, 7:00 AM

BABYF
-2.34%
Else Plant-Based Complete Nutrition for Toddlers is now listed on 900+ retail outlets and currently available for purchase in more than 600 retail outlets. Retail outlets includes Sprouts Farmers Market, Big-Y, Raley's, Natural Grocers, AFS, Haggen, PCC, Mother's Markets and dozens of independent stores.

Else is available online on iHerb (US, Canada, and additional ~180 countries), Thrive Market, amazon.com and elsenutrition.com.

Else is in discussions currently with additional retailers representing over 5000 outlets and with other popular online shopping platforms.

VANCOUVER, BC, June 23, 2021 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company") the plant-based baby, toddler and children nutrition company, is pleased to announce high market penetration and sales growth rates across online and retail channels:

US Product Launch:

Since February 2021, Else Plant-Based Complete Nutrition for Toddlers has been sold in Sprouts Farmers Markets (350 doors) and has expanded to several additional natural food and grocery retailers and independent stores, including Big-Y (71 large format grocery doors), Raley's (126 doors), Natural Grocers (159 doors) AFS (32 doors + 300 potential doors) and more. Else is currently listed in 900+ stores and on the shelves of 600+ of these with continuous rollout to the remaining. The UPSPW KPI (Units per Store per Week) is growing steadily at a month-over-month of an average of 35%.


Else onboarded two of the largest natural food distributors in North America, UNFI and KeHE Distributors, together they cover majority of the retail market in the US. To date, together they have opened 14 of their distribution centers to supply product to retail stores across the US.

Else with its retail brokers, and with the assistance of its distributors, are in discussions with many additional large, small and independent natural food, grocery and drug retail chains, combined represent more than 5,000 retail stores.

Else introduced its first product online in August 2020 on www.elsenutrition.com and in late September on amazon.com. Initial online sales through these two channels indicate a good growth trajectory, with more than 20% month-over-month growth, which is expected to accelerate as more products are added to these channels. From the sales data to date, Else amazon.com monthly sales are doubling approximately every 3-4 months.

The Company plans to list products on additional leading online platforms in the coming months. Else is currently sold on the iHerb, an international online retail platform (US, Canada, 180 international markets) and on Thrive Markets, a leading US online platform that has 500,000+ subscribers.

Recently, June 2021, Else launched a new product line – First of its kind Plant-Based Whole foods Complete Nutrition for Kids, 3 years and older. The product is offered initially in vanilla and chocolate flavors, 16 oz powder cans, with plans for additional flavors in the future. This new product line offers a superior, plant-based, low sugar, delicious alternative to cow milk and soy-based products that are currently in the market.

In the second half of 2021 Else is planning to launch a series of plant-based complementary nutrition products for babies 6 months and older, in several flavors. Early in 2022 the Company plans to launch liquid RTD (Ready-To-Drink) versions of its Complete Nutrition for Kids products.

As additional SKUs are added Else's product range will continue to grow and are expected to further accelerate sales in all channels. These products (in different SKUs and minor variations) will be offered in the USA, Canada, Europe and in other potential markets.

International Product Launch Plans

The Company plans to offer regulatory compliant products for sales in Canada soon, starting online this summer and later in retail stores.

Having developed a line of products which comply with the European Directive, Else is making good progress towards a distribution agreement for France with H&H Group, a strategic investor in Else. Additionally, the Company is in discussions with H&H group for potential distribution of its product line into China via H&H cross-border China platform. International expansion includes plans to offer Else line of products in Europe beginning in Q1 of 2022.

Marketing:
The Company continued to drive customer awareness, conversion, and sales through:

Leveraging key and targeted influencer partnerships including integrated programs with Alicia Silverstone (vegan mom and actor), Hilaria Baldwin (vegan mom and celebrity influencer) and Jade Roper Tolbert and Ali Fedotowsky, both known from ABC's hit show "The Bachelorette."

Adding retail store influencer activities to support retail sales.

Growing the Company's Instagram follower presence to over 12,000 highly engaged and dedicated brand followers.

Major advertising on social channels, as well as the launch of streaming/connected TV campaign (over 5,000,000 impressions).

Phone Image (CNW Group/Else Nutrition Holdings Inc.)
Phone Image (CNW Group/Else Nutrition Holdings Inc.)
Launched a dedicated Else branded storefront on Amazon.com.

Major public relations outreach, including: a dedicated Instagram Live series featuring celebrity/nutritionist conversations about Plant-Based parenting, leading to over 560,000 unique impressions; branded partnerships with ECOS, environmentally safe cleaning products.

Targeted online campaigns supporting the launch of Else Nutrition various retail stores.

Test local TV advertising to add to the marketing mix where suitable.

Launch a comprehensive Health Care Practitioner (HCP) marketing program.

Production:

The company completed its seventh commercial manufacturing run since July 2019 and successfully built inventory to service online and retail expansion in the U.S. market and beyond.

"In the last few months, we have improved our manufacturing process and product quality to consistently produce a high quality and easily dissolved tasty product," said Ms. Hamutal Yitzhak, CEO and Co-Founder of Else. "Our new kids products can be easily prepared in a cup or in a shaker with cold water, something both kids and parents love and appreciate." She added.

Medical Marketing and Scientific Affairs:

The Company is in the process of developing a medical marketing plan for health care professionals, building a U.S. medical sales & marketing team, along with a new website targeted towards the professional community.

The company is conducting several clinical studies to demonstrate scientifically that its line of products supports growth, are well tolerated by young children, as well as those children suffering from various health issues. The company is finalizing protocols for a growth study in healthy toddlers and for a hypo allergenicity study amongst toddlers with cow milk allergy.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Agreed. Hopefully the uplist to global select will eat up the additional shares. Bigger money at play there.

Sue on the offering:

https://finance.yahoo.com/news/hut-8-achieves-record-level-113000661.html

https://www.newswire.ca/news-releases/hut-8-announces-plans-to-list-on-nasdaq-836390207.html

Xcelerate Inc. welcomes Dr. Dilantha Ellegala, FAANS, to our Advisory Board! Dr. Ellegala has received numerous academic and clinical honors and has been consistently recognized for his excellence in patient care for two decades. #Xcelerate #medical #technology #DilanthaEllegala pic.twitter.com/z1rfvj5qNW

— Xcelerate, Inc. (@XcelerateUS) April 13, 2021

Explore the other side of neuroscience with Xcelerate, Inc! #Xcelerate #Neuroscience #medical #technology #medtech pic.twitter.com/ffg73kDNLl

— Xcelerate, Inc. (@XcelerateUS) April 8, 2021

https://www.einnews.com/pr_news/537329436/hut-8-to-join-foundry-usa-pool-adds-14-400-machines-with-5-000-more-to-follow

#KR1 $KROEF
Okay, so finally finished playing catch up on KR1 DD - 4/5 years' of RNS' including 51 active investments and 7 fully exited positions in nearly 100 investment/ selling occasions.

In summary - my mind is 🤯🤯🤯🤯

This company is absolutely unreal.

— lolmcshizz (@lolmcshizz) March 11, 2021

Every operating company I'm an investor in is having their @DanielSLoeb1 "moment" regarding putting #Bitcoin on their balance sheet. Changes in the regulatory environment have changed my mind about participating. I will also invest in sustainable miners to avoid "blood coins". https://t.co/NUSDR0jkuz

— Kevin O'Leary aka Mr. Wonderful (@kevinolearytv) March 1, 2021

I'm not sure if you guys are aware, but there's a pink sheet company that is coming out with a language learning app called "Hey Pal." I'm not an attorney, but it seems a little too close to "Hello Pal" and in the exact same industry. I hold 10K shares here and Hello Pal is obviously first to market, so it seems like this company is ripping off.

ClickStream’s HeyPal(TM) App Launches Successfully in 10 Countries, Users Exchange 4,159 Messages in the First 72 Hours

BEVERLY HILLS, CA / ACCESSWIRE / February 11, 2021 / ClickStream Corp. (OTC PINK:CLIS) a technology company focused on developing apps and digital platforms that disrupt conventional industries announces its subsidiary Nebula Software Corp. has successfully soft-launched the HeyPal™ iOS App in 10 countries on Monday, February 8th. The HeyPal™ app received a total of 429 new members that have exchanged over 4,159 messages between one another since the app was released just 3 days ago.


Frank Magliochetti, CEO of ClickStream, states "The amount of engagement we're seeing from our first batch of users overseas is enlightening. I myself opened a HeyPal™ account as I would like to sharpen my Italian speaking skills, and I have been receiving messages from a large number of members offering to help me on my journey. I wholeheartedly believe language learners all around the world will need to use HeyPal™ as part of their language learning regimen."

Additionally, over 1,538 translations, 367 likes and 169 comments were made on HeyPal's "language feeds" since Monday.

Tristan Chaudhry, CTO of Nebula states, "It's really encouraging to see our new language learning members use the features we have built. We're seeing a repeat usage of the translation features, signaling practicality and effectiveness. I think the level of engagement on the app is especially high because members are entering the app with a specific purpose of exchanging their native languages with one another."

The HeyPal™ iOS app become available on February 8th, 2021 in a select group of countries as part of the soft launch program. HeyPal™ is currently live in 10 countries, including: Australia, Taiwan, Spain, Ireland, Switzerland, Morocco, Ukraine, Turkey, Colombia & Israel.

The online language learning market was valued at USD 12.49 billion in 2019 and is projected to grow at 10.2% per year, reaching over USD 25 billion by 2027 according to Verified Market Research

https://finance.yahoo.com/news/clickstream-heypal-tm-app-launches-133000742.html

https://www.prnewswire.com/news-releases/crypto-mining-opportunities-ramp-up-as-bitcoin-bonanza-causes-demand-to-surge-despite-shortages-301230577.html

https://www.prnewswire.com/news-releases/crypto-mining-opportunities-ramp-up-as-bitcoin-bonanza-causes-demand-to-surge-despite-shortages-301230577.html

You're correct. I follow the yahoo board too and noted that she yet to answer that directly. To me that says she's aware that shareholders want the uplist and the company has to know that it would be very beneficial, especially seeing how MARA and RIOT are doing. I hope they're working on it and just staying quiet. This company is so undervalued. I will say though that Sue does a lot in terms of trying to get the word out about Hut8, but nothing beats the institutional money that comes with an uplist

Has the company made any statements about a possible uplist to Nasdaq? They should clearly be trading around the levels of Riot and MARA

https://finance.yahoo.com/news/canada-life-announces-launch-mutual-124500780.html




More content below

IGIFF
-5.99%
Tue, February 16, 2021, 7:00 AM


More content below

IGIFF
-5.99%
Else' baby and children nutrition products will be sold via the iHerb global network into millions of potential customers in over 180+ countries worldwide

VANCOUVER, BC, Feb. 16, 2021 /CNW/ - ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) ("Else" or the "Company") the plant-based baby, toddler and children nutrition company, announces it has signed an agreement with U.S. based international online retailer of wellness and nutrition products, iHerb Inc. The agreement opens a massive gateway to global sales of the Else Nutrition products beyond the U.S.

iHerb (CNW Group/Else Nutrition Holdings Inc.)
iHerb (CNW Group/Else Nutrition Holdings Inc.)
Parents seeking healthier plant-based nutrition alternatives for their children, will shortly be able to find Else's Plant-Based Complete Nutrition products for Toddlers product on iHerb.com.

"Partnering with iHerb is an exciting development on multiple levels, "said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. "In addition to our mutual commitment to support a healthier, more sustainable planet, iHerb immediately enables Else to expand our product offering globally into hundreds of new countries and markets including Canada and Europe.".

About iHerb, Inc.

iHerb, Inc. retails nutritional and healthcare products across the United States and globally. The Company provides supplements, herbs, bathing and beauty products, grocery, kids accessories, and sports goods. Since 1996, the foundation and mission of iHerb has been built on providing a wide selection of health and wellness products to individuals around the globe at a reasonable cost. With a headquarters in Morena Valley, California and various warehouses in the United States, iHerb's team of 1,600 dedicated professionals is deeply committed to the environment, and through several different eco-friendly initiatives, promotes recycling and the limit of waste throughout the company.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

What’s the current share structure here?

Check out the Yahoo Finance board for this. Tons of DD. The head of IR, Sue, posts there quite often and answers questions.

Simon-Barnett By Simon Barnett | @sbarnettARK
Analyst

During the J.P. Morgan Healthcare Conference last week, Invitae (NVTA), a leading medical genetics company, and Pacific Biosciences “PacBio” (PACB), a provider of long-read sequencing instruments, announced a collaboration to develop an ultra-high-throughput sequencing platform based on PacBio’s HiFi sequencing chemistry. This collaboration could increase the number of threats to companies focused on short-read sequencing.

Bolstered not only by results from this year’s PrecisionFDA Truth Challenge but also by improvements in HiFi accuracy via Google’s (GOOGL) DeepVariant as well as research community feedback, we think PacBio’s HiFi sequencing method provides the most complete and accurate view of the human genome.

To drive widespread adoption, PacBio likely needs to improve instrument throughput and variable cost. Collaborating with Invitae, we imagine PacBio can gain critical insights into its customers’ challenges, from automated sample prep to large-scale data processing. Invitae’s high sample volume could help PacBio’s long-read sequencing to capitalize on its Wright’s Law curve, as costs decline 28% for every cumulative doubling in the number of whole human genomes sequenced on long-read machines.

In our opinion, HiFi sequencing should help Invitae pull further away from its competition in the molecular diagnostics space, enabling the detection and evaluation of hard-to-sequence variants that could change patient management meaningfully. Unlike with short-read sequencing, HiFi-sequenced genomes should allow for the digital reassessment of patients’ DNA throughout their lifetimes, especially as researchers learn more about hard-to-sequence genes and the effects of structural variation within the human genome.

Ultimately, we believe the combination of talent, resources, know-how, and sample volume should allow both companies push long-read sequencing into routine medical practice faster than otherwise would be the case. By publishing data on clinical utility and diagnostic yields across disease types, they also should be able to demonstrate the system-wide value of HiFi sequencing over short-read whole genome sequencing.

https://www.bio-itworld.com/news/2021/01/15/pacbio-year-of-expansion-whole-genome-clinical-goals